Baidu
map

天津医科大学发现肿瘤招募干细胞促进肿瘤生长和进展的新机制

2016-10-24 佚名 生物谷

最近一项新研究发现了肿瘤从骨招募干细胞将其转变为癌相关成纤维细胞进而促进肿瘤进展的新机制。这项工作准确地找到了参与上述过程的生化途径和细胞信号分子,或为抑制肿瘤生长提供新的治疗靶点。相关研究结果发表在国际学术期刊Stem Cells and Development上。这项研究由天津医科大学的Xue Yang和Xiong-Zhi Wu等人完成,他们在题为“bFGF Promotes Migratio


最近一项新研究发现了肿瘤从骨招募干细胞将其转变为癌相关成纤维细胞进而促进肿瘤进展的新机制。这项工作准确地找到了参与上述过程的生化途径和细胞信号分子,或为抑制肿瘤生长提供新的治疗靶点。相关研究结果发表在国际学术期刊Stem Cells and Development上。

这项研究由天津医科大学的Xue Yang和Xiong-Zhi Wu等人完成,他们在题为“bFGF Promotes Migration and Induces Cancer-associated Fibroblasts Differentiation of Mouse Bone Mesenchymal Stem Cells to Promote Tumor Growth”的文章中详细介绍了他们的结果。研究人员发现乳腺癌细胞利用bFGF(basic fibroblast growth factor)信号帮助它们吸引骨来源的间充质干细胞,并诱导这些间充质干细胞变成癌相关成纤维细胞。他们在文章中展示了干细胞招募和癌相关成纤维细胞的促肿瘤进展功能,并且发现这种作用主要通过影响肿瘤微环境来实现。

“通过这篇文章我们对肿瘤如何招募间充质干细胞并将其诱导为癌相关成纤维细胞进而促进肿瘤进展有了更加深入的认识,”杂志主编来自美国韦恩州立大学医学院的Graham C. Parker博士这样说道。“对bFGF信号途径的进一步认识不仅加深了人们对于上述过程的了解,同时也为癌症治疗提供了一些新的靶点。”

原始出处

Yang Xue, Hao Jian, Mao Yu, Jin Zi-Qi, Cao Rui, Zhu Cui-Hong, Liu Xiao-Hui, Liu Chang, Ding Xiu-Li, Wang Xiao-Dong, Chen Dan, and Wu Xiong-Zhi.bFGF promotes migration and induces cancer-associated fibroblasts differentiation of mouse bone mesenchymal stem cells to promote tumor growth.Stem Cells and Development.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1923105, encodeId=870e1923105fb, content=<a href='/topic/show?id=97f835221ba' target=_blank style='color:#2F92EE;'>#医科大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35221, encryptionId=97f835221ba, topicName=医科大学)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Thu Apr 20 04:56:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548505, encodeId=033e154850591, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Wed Oct 26 10:56:00 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150977, encodeId=ed391509e74e, content=好,讲的有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Oct 25 00:58:22 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150961, encodeId=0e50150961b9, content=这个可以噢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161003/IMG57F1CE4724D2E2574.jpg, createdBy=c2eb1960303, createdName=drmike, createdTime=Tue Oct 25 00:18:24 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1923105, encodeId=870e1923105fb, content=<a href='/topic/show?id=97f835221ba' target=_blank style='color:#2F92EE;'>#医科大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35221, encryptionId=97f835221ba, topicName=医科大学)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Thu Apr 20 04:56:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548505, encodeId=033e154850591, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Wed Oct 26 10:56:00 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150977, encodeId=ed391509e74e, content=好,讲的有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Oct 25 00:58:22 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150961, encodeId=0e50150961b9, content=这个可以噢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161003/IMG57F1CE4724D2E2574.jpg, createdBy=c2eb1960303, createdName=drmike, createdTime=Tue Oct 25 00:18:24 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1923105, encodeId=870e1923105fb, content=<a href='/topic/show?id=97f835221ba' target=_blank style='color:#2F92EE;'>#医科大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35221, encryptionId=97f835221ba, topicName=医科大学)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Thu Apr 20 04:56:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548505, encodeId=033e154850591, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Wed Oct 26 10:56:00 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150977, encodeId=ed391509e74e, content=好,讲的有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Oct 25 00:58:22 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150961, encodeId=0e50150961b9, content=这个可以噢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161003/IMG57F1CE4724D2E2574.jpg, createdBy=c2eb1960303, createdName=drmike, createdTime=Tue Oct 25 00:18:24 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
    2016-10-25 zhuzhuba1

    好,讲的有道理

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1923105, encodeId=870e1923105fb, content=<a href='/topic/show?id=97f835221ba' target=_blank style='color:#2F92EE;'>#医科大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35221, encryptionId=97f835221ba, topicName=医科大学)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Thu Apr 20 04:56:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548505, encodeId=033e154850591, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Wed Oct 26 10:56:00 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150977, encodeId=ed391509e74e, content=好,讲的有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Oct 25 00:58:22 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150961, encodeId=0e50150961b9, content=这个可以噢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161003/IMG57F1CE4724D2E2574.jpg, createdBy=c2eb1960303, createdName=drmike, createdTime=Tue Oct 25 00:18:24 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
    2016-10-25 drmike

    这个可以噢!

    0

相关资讯

JAMA Oncol:注意!口服化疗药物治疗时,联用质子泵抑制剂,会导致更差的生存!

卡培他滨是常使用的口服化疗药之一,与其他口服药物一起服用时,卡培他滨可能会受到药物间相互作用影响,不利于药物的吸收。 本研究的目的是,探究如质子泵抑制剂(PPIs)等胃酸抑制剂,是否会对卡培他滨的疗效不利。 研究纳入了545例ERBB2/HER2阳性的性转移性食管癌(GEC)患者,按1:1随机分为卡培他滨和奥沙利铂(CapeOx)伴或不伴拉帕替尼。比较使用或没有使用PPIs患者的无进展

我国科学家定义广谱肿瘤标志物Hsp90α获准用于临床

10月19日,清华大学对外宣布,该校教授、抗肿瘤蛋白质药物国家工程实验室主任罗永章领导的团队在世界上首次证明,肿瘤标志物热休克蛋白90α(Hsp90α)可用于肝癌患者的检测,其自主研发的Hsp90α定量检测试剂盒现已被国家食品药品监督管理总局批准在临床中使用,这也标志着首个由我国科学家定义、并获准用于临床的广谱肿瘤标志物的诞生,对提高癌症诊疗水平具有深远的意义。 据介绍,肿瘤标志物是由肿瘤

NEJM:这份案例的开头很羞羞,结局却出乎意料!——案例报道

患者男,20岁,双侧乳房渐丰满3年,无乳头溢液。偶有早搏,没有性冲动,不手淫。 4年前,患者出现口渴、液体摄入量增多和排尿次数的增加,白天排尿4-5次,夜晚排尿高达3次。怀疑糖尿病,但糖尿病相关检测均阴性。 在最近几个月,排尿的频率下降,口渴感恢复正常。 患者视力模糊数年,带框架眼镜矫正,无复视及劳累,偶有头痛。 自述青春期是正常的。 大约8个月前,患者剃胡须的频率下

JCEM:叶切除术会增加甲状腺乳头状癌复发风险?

研究数据显示,对于小乳头状甲状腺癌成年患者,接受叶切除术或肿瘤直径至少1.8 cm,两个或两个以上转移性淋巴结或双侧肿瘤,患者的长期复发风险增加。 韩国国立首尔大学医学院的Ka Hee Yi博士和同事进行了一项全国性的、回顾性、多中心研究,包括3282名(平均年龄47岁)甲状腺乳头状癌成年患者,肿瘤直径不超过2 cm。 平均随访5.8年。评估与长期复发相关的高危因素。 总的来说,

试验表明索坦辅助治疗可延长肾细胞癌患者术后无病生存期

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_

Baidu
map
Baidu
map
Baidu
map